Satellos Bioscicence Inc.
Symbol: TSXV: MSCL OTCQB: MSCLF
Market Cap: Private
- Satellos Bioscience Inc. is a biotechnology company developing small molecule drugs to restore the regenerative capacity of muscle as a disease modifying therapeutic approach to devastating muscle conditions
- The Company’s lead program is focused on correcting a regeneration deficit it discovered to be a root cause of the progressive muscle loss in Duchenne muscular dystrophy, a lethal genetic disease with no cure
- Satellos believes its technology is game changing and can be applied to a range of dystrophies, atrophies and fraility/aging.